# HER2CLIMB-04 (NCT04539938)

> A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04539938
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: HER2 Positive Breast Cancer
- Interventions: tucatinib; trastuzumab deruxtecan
- Enrollment: 70
- Primary outcome: Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=her2climb-04-nct04539938

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04539938", "email": "<work email>"}; the inbox owner confirms by the emailed link.